Acadia Pharmaceuticals (ACAD) Fundamental Analysis: Revenue, Earnings & Valuation

6.41 / 10

Outperform

Fundamentally, Acadia rates Outperform with a 6.4/10 rating. Strong cash‑to‑market and PB‑ROE metrics, solid asset‑to‑market positioning, and 11.9% YoY revenue growth support its health. However, revenue‑to‑market and gross profit margin lag, tempering the outlook.

Analysis Checks(8/10)

Revenue-MV

Value-0.58

Score1/3

Weight18.18%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value11.87

Score3/3

Weight4.70%

1M Return1.54%

Inventory turnover ratio

Value3.14

Score2/3

Weight-3.39%

1M Return-1.21%

Gross profit margin (%)

Value91.69

Score0/3

Weight-17.64%

1M Return-7.24%

PB-ROE

Value1.78

Score3/3

Weight37.82%

1M Return9.74%

Income tax / Total profit (%)

Value-181.49

Score3/3

Weight5.49%

1M Return1.47%

Fixed assets turnover ratio

Value20.28

Score2/3

Weight-1.60%

1M Return-0.51%

Cost of sales ratio (%)

Value8.31

Score2/3

Weight-11.58%

1M Return-4.42%

Asset-MV

Value-0.55

Score2/3

Weight46.62%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight21.42%

1M Return5.94%

Is ACAD undervalued or overvalued?

ACAD scores 6.41/10 on fundamentals and holds a Discounted valuation at present. Backed by its 39.89% ROE, 36.49% net margin, 9.05 P/E ratio, 2.88 P/B ratio, and 69.34% earnings growth, these metrics solidify its Outperform investment rating.